Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 5/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | LIG1 | P18858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11131345 | 0.84 | LMNA (0.38) | LMNAHPGDPOLBRAB9AALDH1A1 | |
| SCHEMBL11133927 | 0.79 | STING1 (0.40) | — | |
| SCHEMBL9807575 | 0.77 | LMNA (0.40) | LMNAKDM4EHPGDRAB9AALDH1A1 | |
| SCHEMBL1948464 | 0.77 | KDM4E (0.46) | KDM4EHPGDPOLBRAB9AALDH1A1 | |
| SCHEMBL25382116 | 0.74 | LMNA (0.37) | LMNAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL10645494 | 0.74 | ALDH1A1 (0.50) | LMNAKDM4EHPGDMEN1KMT2A | |
| SCHEMBL4204419 | 0.73 | POLB (0.40) | LMNAKDM4EMEN1KMT2APOLB | |
| SCHEMBL4463189 | 0.73 | ADORA2A (0.41) | LMNAKDM4EMEN1KMT2ARAB9A | |
| SCHEMBL18331573 | 0.73 | NOTUM (0.40) | LMNAKDM4EMEN1KMT2ARAB9A | |
| SCHEMBL11185171 | 0.73 | NOTUM (0.40) | LMNAKDM4EMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752615-B2 | Spirocyclic containing compounds and pharmaceutical uses thereof | GB005, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190263790-A1 | SPIROCYCLIC CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF | GB005, INC. | 2019-08-29 | — | — | US | disclosed |
| US-9932329-B2 | Benzimidazole derivatives as RLK and ITK inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932329-B2 | Benzimidazole derivatives as RLK and ITK inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932329-B2 | Benzimidazole derivatives as RLK and ITK inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| WO-2018032104-A1 | SPIROCYCLIC CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PHARMASCIENCE INC. (CA) | 2018-02-22 | — | — | WO | disclosed |
| EP-3114124-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2017-01-11 | — | — | EP | disclosed |
| US-20160368908-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS | PRINCIPIA BIOPHARMA, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160368908-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS | PRINCIPIA BIOPHARMA, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160368908-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS | PRINCIPIA BIOPHARMA, INC. | 2016-12-22 | — | — | US | disclosed |
| WO-2015134210-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368908-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS | ITK, BLK, LMTK2 | LMNA 1240/4885PTGER1 2759/4885KDM4E 2697/4885 |
| US-10752615-B2 | Spirocyclic containing compounds and pharmaceutical uses thereof | TEC, ITK, TXK | LMNA 3282/4885PTGER1 972/4885KDM4E 3749/4885 |
| US-20190263790-A1 | SPIROCYCLIC CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF | TEC, ITK, TXK | LMNA 3282/4885PTGER1 972/4885KDM4E 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.